School of Chemical Engineering and Physical Sciences, Lovely Professional University, Phagwara 144411, India.
School of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology, Patiala 147004, India.
Mini Rev Med Chem. 2021;21(8):952-968. doi: 10.2174/1389557520666201124141103.
The recent emergence of novel, pathogenic COVID-19 disease associated with SARSCoV- 2 virus in China and its rapid national and international spread pose a global health emergency. The development of a new drug is tedious and may take decades to develop and involve multiple steps like the development of prototypes and phase I to III human trials, which involve the study on small to large populations to examine the safety and side effects associated with the drug under trials. Due to continous increase in the number of confirmed cases and deaths, there is an urgent need to develop a drug that is effective to kill the SARS-CoV-2 virus with fewer side effects to the human body. Therefore, this review focus on the latest advances in the development for the treatment of COVID-19 disease associated with SARS-CoV-2 with repositioning of already marketed drug with small molecules, as well as Chinese traditional medicines with established safety and efficacy which are being used for different therapeutic uses.
新型 SARS-CoV-2 病毒引起的、与 COVID-19 相关的疾病最近在中国出现,并迅速在国内和国际传播,构成了全球卫生紧急事件。开发新药繁琐,可能需要数十年的时间,涉及多个步骤,如原型的开发和 I 期到 III 期人体试验,这涉及从小规模到大规模人群的研究,以检查试验药物相关的安全性和副作用。由于确诊病例和死亡人数不断增加,因此迫切需要开发一种有效杀死 SARS-CoV-2 病毒、对人体副作用较小的药物。因此,本综述重点介绍了利用已经上市的小分子药物重新定位,以及具有既定安全性和疗效的中药治疗 COVID-19 疾病的最新进展,这些中药正在用于不同的治疗用途。